Want to see SHC full AI Analyst Report?
SHC Stock Chart & Stats
$17.35
-$0.14(-0.80%)
At close: 4:00 PM EDT
$17.35
-$0.14(-0.80%)
Day’s Range― - ―
52-Week Range$12.95 - $19.85
Previous Close$17.35
Volume2.43M
Average Volume (3M)2.71M
Market Cap
$5.09B
Enterprise Value$6.93K
Total Cash (Recent Filing)$356.73M
Total Debt (Recent Filing)$2.27B
Price to Earnings (P/E)43.4
Beta1.22
Next Earnings
Nov 10, 2026EPS Estimate
0.27Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.57
Shares Outstanding285,167,000
10 Day Avg. Volume3,017,015
30 Day Avg. Volume2,708,915
Financial Highlights & Ratios
PEG Ratio0.95
Price to Book (P/B)8.27
Price to Sales (P/S)4.30
P/FCF Ratio33.58
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$23.67Price Target Upside36.41% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)0.97
Revenue Forecast (FY)$1.24B
Bulls Say, Bears Say
Bulls Say
Essential, Recurring ServicesSotera’s core sterilization, irradiation and testing services are regulatory necessities for device and pharma makers, creating recurring demand and high switching costs. Outsourcing of compliance-intensive processes supports durable revenue visibility and long-term customer relationships.
High And Improving MarginsSustained high gross and adjusted EBITDA margins reflect pricing power, operational scale and favorable mix (notably Nordion’s and Sterigenics’ margins). Margin expansion enhances cash generation potential and resilience to cost inflation over a multi‑quarter horizon.
Refinancing And Leverage ProgressRepriced term debt and a move toward target 2–3x net leverage reduce interest burden and lengthen maturities. That structural improvement increases financial flexibility to fund capex, organic growth and continued deleveraging without immediate liquidity strain.
Bears Say
Elevated LeverageSotera’s elevated leverage constrains strategic optionality and increases sensitivity to interest-rate moves or cash-flow shocks. A relatively small equity base magnifies ROE but leaves less cushion versus adverse operational or legal outcomes over the next several quarters.
Volatile Free Cash FlowInconsistent FCF and low conversion versus earnings limit capacity to pay down debt, sustain elevated capex, or absorb one-time costs. Historical swings (including periods of negative FCF) raise execution risk during growth investments and litigation periods.
Ongoing Litigation OverhangActive, multi-jurisdictional litigation creates potential for material settlements, defense costs and operational distraction. Uncertainty on timing and outcomes can impair customer negotiations, raise compliance costs, and keep a structural risk premium on the business for many months.
Sotera Health News
SHC FAQ
What was Sotera Health Company’s price range in the past 12 months?
Sotera Health Company lowest stock price was $12.95 and its highest was $19.85 in the past 12 months.
What is Sotera Health Company’s market cap?
Sotera Health Company’s market cap is $5.09B.
When is Sotera Health Company’s upcoming earnings report date?
Sotera Health Company’s upcoming earnings report date is Nov 10, 2026 which is in 92 days.
How were Sotera Health Company’s earnings last quarter?
Sotera Health Company released its earnings results on Aug 06, 2026. The company reported $0.26 earnings per share for the quarter, beating the consensus estimate of $0.239 by $0.021.
Is Sotera Health Company overvalued?
According to Wall Street analysts Sotera Health Company’s price is currently Undervalued.
Does Sotera Health Company pay dividends?
Sotera Health Company does not currently pay dividends.
What is Sotera Health Company’s EPS estimate?
Sotera Health Company’s EPS estimate is 0.27.
How many shares outstanding does Sotera Health Company have?
Sotera Health Company has 285,167,000 shares outstanding.
What happened to Sotera Health Company’s price movement after its last earnings report?
Sotera Health Company reported an EPS of $0.26 in its last earnings report, beating expectations of $0.239. Following the earnings report the stock price went up 5.172%.
Which hedge fund is a major shareholder of Sotera Health Company?
Currently, no hedge funds are holding shares in SHC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Sotera Health Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$23.67 (36.41% Upside)
$23.67 (36.41% Upside)
Blogger Sentiment
Bullish
SHC Sentiment 75%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 521.7K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $482.7M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▲ 3.2%
Last 30 Days ▲ 0.5%
Last 30 Days ▲ 0.5%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
43.27%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
2.80%
Trailing 12-Months
Company Description
Sotera Health Company
Sotera Health Company, headquartered in Broadview Heights, Ohio, delivers essential sterilization, laboratory testing, and advisory services to a global clientele spanning North America, Europe, and various international regions. The firm's sterilization capabilities encompass gamma and electron beam irradiation, alongside ethylene oxide (EO) processing. Through its Nelson Labs division, Sotera Health conducts comprehensive microbiological and analytical chemistry analyses. Additionally, it offers specialized consulting to the medical device and biopharmaceutical industries. Sotera Health serves a diverse array of sectors, including medical device manufacturers, pharmaceutical companies, producers of food and agricultural products, and various commercial, advanced, and specialty application industries. Incorporated in 2017, the company was previously known as Sotera Health Topco, Inc., adopting its current name in October 2020.
SHC Company Deck
SHC Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call highlights strong operational execution across the portfolio, with double-digit growth in adjusted EBITDA, revenue beats, margin expansion, improved leverage, lowered interest costs and a raised full-year outlook. Segment-level strength was notable at Sterigenics and Nordion, and Nelson Labs showed recovering sequential margins though year-over-year margin pressures remain. Near-term risks include inflationary cost pressure, FX variability, elevated capital spending (and higher depreciation), timing volatility in Nordion shipments, and ongoing litigation. Taken together, the positives (organic growth, margin expansion, guidance raise, balance sheet improvement) materially outweigh the manageable operational and legal headwinds.View all SHC earnings summariesSHC Stock 12 Month Forecast
Average Price Target
$23.67
▲(36.41% Upside)
Technical Analysis
Charles River Labs
―
Labcorp Holdings
―
Quest Diagnostics
―
Thermo Fisher
―
IQVIA Holdings
―
Ownership Overview
2.75% Insiders
16.11% Mutual Funds
1.99% Other Institutional Investors
60.21% Public Companies and
Individual Investors